VKTX - Viking Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
VKTX price evolution
VKTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $43.95 | $195.61 | $55.55 | |
| Short term investments | $898.35 | $767.4 | $306.56 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $936.65 | $945.72 | $966.34 | $367.23 |
| Long term investments | ||||
| Property, plant & equipment | $1.11 | $0.98 | $1.05 | $1.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.11 | $1.18 | $1.26 | |
| Total investments | $898.35 | $767.4 | $306.56 | |
| Total assets | $937.89 | $946.84 | $967.52 | $368.49 |
| Current liabilities | ||||
| Accounts payable | $0.25 | $11.09 | $5.22 | $7.51 |
| Deferred revenue | ||||
| Short long term debt | $0.33 | $0.33 | $0.32 | |
| Total current liabilities | $25.68 | $25.09 | $32.77 | $19.14 |
| Long term debt | $0.77 | $0.85 | $0.94 | |
| Total noncurrent liabilities | $0.77 | $0.85 | $0.94 | |
| Total debt | $1.1 | $1.18 | $1.26 | |
| Total liabilities | $26.44 | $25.86 | $33.63 | $20.07 |
| Shareholders' equity | ||||
| Retained earnings | -$452.49 | -$427.55 | -$405.3 | -$377.94 |
| Other shareholder equity | $1.63 | -$2.27 | -$1.6 | -$0.39 |
| Total shareholder equity | $920.98 | $933.89 | $348.42 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $55.55 | $36.63 | $26.37 | $29.1 |
| Short term investments | $306.56 | $118.85 | $175.73 | $219.27 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $367.23 | $167.04 | $210.53 | $256.1 |
| Long term investments | ||||
| Property, plant & equipment | $1.13 | $1.42 | $0.03 | $0.3 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.26 | $1.49 | $0.13 | $0.4 |
| Total investments | $306.56 | $118.85 | $175.73 | $219.27 |
| Total assets | $368.49 | $168.53 | $210.66 | $256.5 |
| Current liabilities | ||||
| Accounts payable | $7.51 | $8.53 | $1.44 | $4 |
| Deferred revenue | ||||
| Short long term debt | $0.32 | $0.3 | $0.03 | $0.33 |
| Total current liabilities | $19.14 | $21.95 | $8.78 | $12.1 |
| Long term debt | $0.94 | $1.26 | $0.03 | |
| Total noncurrent liabilities | $0.94 | $1.26 | $0.03 | |
| Total debt | $1.26 | $1.56 | $0.03 | $0.36 |
| Total liabilities | $20.07 | $23.21 | $8.78 | $12.2 |
| Shareholders' equity | ||||
| Retained earnings | -$377.94 | -$292.05 | -$223.18 | -$168.2 |
| Other shareholder equity | -$0.39 | -$1.1 | -$0.55 | -$0.1 |
| Total shareholder equity | $348.42 | $145.32 | $201.88 | $244.34 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $23.77 | $24.1 | $20.5 | |
| Selling, general & administrative | $10.29 | $9.97 | $8.78 | |
| Total operating expenses | $36.56 | $34.05 | $34.07 | $29.29 |
| Operating income | -$34.05 | -$34.07 | -$29.29 | |
| Income from continuing operations | ||||
| EBIT | -$22.25 | -$27.36 | -$24.61 | |
| Income tax expense | ||||
| Interest expense | $11.62 | |||
| Net income | ||||
| Net income | -$24.94 | -$22.25 | -$27.36 | -$24.61 |
| Income (for common shares) | -$22.25 | -$27.36 | -$24.61 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $63.81 | $54.23 | $44.98 | $31.93 |
| Selling, general & administrative | $37.02 | $16.12 | $10.7 | $10.73 |
| Total operating expenses | $100.83 | $70.36 | $55.68 | $42.66 |
| Operating income | -$100.83 | -$70.36 | -$55.68 | -$42.66 |
| Income from continuing operations | ||||
| EBIT | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
| Income (for common shares) | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$22.25 | -$27.36 | -$24.61 | |
| Operating activities | ||||
| Depreciation | $0.07 | $0.07 | $0.07 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.08 | $7.98 | $4.08 | |
| Total cash flows from operations | -$28.51 | -$6.13 | -$17.64 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$126.06 | -$459.79 | $35.73 | |
| Total cash flows from investing | -$559.95 | -$126.06 | -$459.79 | $35.73 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.9 | $648.14 | $0.19 | |
| Net borrowings | ||||
| Total cash flows from financing | $611.46 | $2.9 | $606.04 | $0.19 |
| Effect of exchange rate | -$0.07 | $0 | -$0.05 | $0.05 |
| Change in cash and equivalents | -$5.17 | -$151.67 | $140.11 | $18.28 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$85.89 | -$68.87 | -$54.99 | -$39.49 |
| Operating activities | ||||
| Depreciation | $0.29 | $0.29 | $0.3 | $0.28 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16.75 | $8.67 | $6.1 | $5.82 |
| Total cash flows from operations | -$73.38 | -$48.4 | -$47.59 | -$21.78 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$179.09 | $54.75 | $37.96 | $41.57 |
| Total cash flows from investing | -$179.09 | $54.75 | $37.96 | $41.57 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $278.5 | $5.72 | $7.63 | $1.27 |
| Net borrowings | ||||
| Total cash flows from financing | $271.38 | $4.16 | $6.88 | $0.95 |
| Effect of exchange rate | -$0.03 | -$0.26 | ||
| Change in cash and equivalents | $18.91 | $10.52 | -$2.75 | $20.74 |
News
Fundamentals
| Market cap | $3.28B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 111.43M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$99.15M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -33.05 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.89 |
|---|---|
| ROA | -12.31% |
| ROE | N/A |
| Debt/Equity | 0.06 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 36.47 |
| Quick ratio | N/A |